Calciphylaxis: case report of a young women with necrotic lower extremity lesions
Abstract
Calciphylaxis is a rare disease characterized by arteriolar medial calcification, vascular thrombosis, intimal hyperplasia, ulceration and areas of necrosis. It most commonly affects patients on hemodyalisis, but although patients without renal disease can be affected too. In these it is named as not uremic calciphylaxis and the most frequent causes are primary hyperparathyroidism, connective tissue diseases, alcoholic liver disease, and neoplasms. It’s important to keep in mind that calciphylaxis can be easily mistaken for vascultis, even in those without a history of rheumatologic disease. So it should be taken into consideration before a patient with painful ulcers of lower limb difficult to heal.Downloads
References
(1) Weenig RH, Sewell LD, Davis MD, McCarthy JT, Pittelkow MR. Calciphylaxis: natural history, risk factor analysis, and outcome. J Am Acad Dermatol. 2007;56(4):569-79.
(2) L ee JL, Naguwa SM, Cheema G, Gershwin ME. Recognizing calcific uremic arteriolopathy in autoimmune disease: an emerging mimicker of vasculitis. Autoimmun Rev. 2008;7(8):638-43.
(3) Naik BJ, Lynch DJ, Slavcheva EG, Beissner RS. Calciphylaxis: medical and surgical management of chronic extensive wounds in a renal dialysis population. Plast Reconstr Surg. 2004;113(1):304-12.
(4) Nigwekar SU, Wolf M, Sterns RH, Hix JK. Calciphylaxis from nonuremic causes: a systematic review. Clin J Am Soc Nephrol. 2008;3(4):1139-43.
(5) Schafer C, Heiss A, Schwarz A, Westenfeld R, Ketteler M, Floege J, et al. The serum protein alpha 2-Heremans-Schmid glycoprotein/ fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest. 2003;112(3):357-66.
(6) Ng AT, Peng DH. Calciphylaxis. Dermatol Ther. 2011;24(2):256-62.
(7) Buerger L. Landmark.Thrombo-angiitis obliterans: a study of the vascular lesions leading to presenile spontaneous gangrene. Am J Med Sci. 2009;337(4):274-84.
(8) Carlson JA, Chen KR. Cutaneous pseudovasculitis. Am J Dermatopathol. 2007;29(1):44-55.
(9) Bechara FG, Altmeyer P, Kreuter A. Should we perform surgical debridement in calciphylaxis? Dermatol Surg. 2009;35(3):554-5.
(10) Polizzotto MN, Bryan T, Ashby MA, Martin P. Symptomatic manage-ment of calciphylaxis: a case series and review of the literature. J Pain Symptom Manage. 2006;32(2):186-90.
(11) Perkovic V, Neal B. Trials in kidney disease--time to EVOLVE. N EnglJ Med. 2012;367(26):2541-2.
(12) Brandenburg V, Adragao T, van Dam B, Evenepoel P, Frazao JM,Ketteler M, et al. Blueprint for a European calciphylaxis registry initiative: the European Calciphylaxis Network (EuCalNet). Clin Kidney J. 2015;8(5):567-71.
